A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Oral Formulation and Determination of Intravenous Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs MEDI-7219 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 13 Sep 2019 Planned number of patients changed from 118 to 130.
- 07 Jun 2019 Planned End Date changed from 29 Sep 2019 to 13 Apr 2020.
- 07 Jun 2019 Planned primary completion date changed from 29 Sep 2019 to 13 Apr 2020.